Pharmaceutical and medical device manufacturers launching their first product in the US face several complex challenges while preparing for the required collection and reporting of transfer
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh